US Stock Market Move | Eli Lilly (LLY.US) fell by 3.9% against the market, oral weight loss drug Foundayo has a lower prescription volume than Novo Nordisk A/S Sponsored ADR Class B (NVO.US).

On Friday, the stock price of Eli Lilly (LLY.US) plummeted against the market trend, dropping by 3.9% to $881.648 as of the time of writing. The company's newly launched oral weight loss drug Foundayo had much lower prescription levels than its competitor Novo Nordisk A/S Sponsored ADR Class B (NVO.US). Novo Nordisk A/S Sponsored ADR Class B saw a price increase of over 6%, reaching $40.875. Data shows that Foundayo generated a total of 3707 prescriptions in its second week on the market, while Novo Nordisk A/S Sponsored ADR Class B's oral version Wegovy received 18410 prescriptions in the same period. Analysts point out that in the oral weight loss drug market, Novo Nordisk A/S Sponsored ADR Class B may maintain its leading position due to its more competitive products.